CL2021001587A1 - Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf - Google Patents
Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegfInfo
- Publication number
- CL2021001587A1 CL2021001587A1 CL2021001587A CL2021001587A CL2021001587A1 CL 2021001587 A1 CL2021001587 A1 CL 2021001587A1 CL 2021001587 A CL2021001587 A CL 2021001587A CL 2021001587 A CL2021001587 A CL 2021001587A CL 2021001587 A1 CL2021001587 A1 CL 2021001587A1
- Authority
- CL
- Chile
- Prior art keywords
- high concentration
- antibody
- protein solution
- formulation containing
- vegf antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación proporciona anticuerpos anti-VEGF formulados como alta concentración, composiciones farmacéuticas acuosas, adecuadas para una inyección, con preferencia una inyección intravítrea. Las composiciones farmacéuticas acuosas son útiles para el suministro de una alta concentración del ingrediente activo del anticuerpo a un paciente sin altos niveles de agregación de anticuerpos y sin un alto nivel de material particulado sub-visible. Una composición acuosa de la divulgación comprende un anticuerpo que tiene una concentración de al menos 50 mg/ml. Una composición farmacéutica acuosa de la divulgación incluye un azúcar, un agente tamponador, y un surfactante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781003P | 2018-12-18 | 2018-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001587A1 true CL2021001587A1 (es) | 2022-02-11 |
Family
ID=69165422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001587A CL2021001587A1 (es) | 2018-12-18 | 2021-06-16 | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11945859B2 (es) |
| EP (1) | EP3897714A1 (es) |
| JP (2) | JP7089121B2 (es) |
| KR (1) | KR20210106476A (es) |
| CN (1) | CN113194993A (es) |
| AR (1) | AR117707A1 (es) |
| AU (1) | AU2019407063B2 (es) |
| BR (1) | BR112021011290A2 (es) |
| CA (1) | CA3119241A1 (es) |
| CL (1) | CL2021001587A1 (es) |
| CO (1) | CO2021007830A2 (es) |
| CR (1) | CR20210318A (es) |
| EC (1) | ECSP21043639A (es) |
| IL (1) | IL283456A (es) |
| JO (1) | JOP20210152A1 (es) |
| MX (1) | MX2021007393A (es) |
| PE (1) | PE20211602A1 (es) |
| SG (1) | SG11202104653XA (es) |
| WO (1) | WO2020128792A1 (es) |
| ZA (1) | ZA202102986B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2307458T1 (en) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
| PL2307457T5 (pl) | 2008-06-25 | 2022-12-27 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące tnf |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL2307457T5 (pl) | 2008-06-25 | 2022-12-27 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące tnf |
| DK3216803T3 (da) | 2008-06-25 | 2020-06-02 | Novartis Ag | Stabile og opløselige antistoffer, der hæmmer vegf |
| SI2307458T1 (en) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
| US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| EP2721048A1 (en) | 2011-06-16 | 2014-04-23 | Lonza Ltd | A process for extraction of peptides and its application in liquid phase peptide synthesis |
| KR20140045440A (ko) | 2011-06-30 | 2014-04-16 | 제넨테크, 인크. | 항-c-met 항체 제제 |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| KR20200131839A (ko) | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
-
2019
- 2019-12-16 MX MX2021007393A patent/MX2021007393A/es unknown
- 2019-12-16 BR BR112021011290A patent/BR112021011290A2/pt unknown
- 2019-12-16 PE PE2021000916A patent/PE20211602A1/es unknown
- 2019-12-16 JO JOP/2021/0152A patent/JOP20210152A1/ar unknown
- 2019-12-16 SG SG11202104653XA patent/SG11202104653XA/en unknown
- 2019-12-16 CR CR20210318A patent/CR20210318A/es unknown
- 2019-12-16 KR KR1020217021741A patent/KR20210106476A/ko unknown
- 2019-12-16 JP JP2021534608A patent/JP7089121B2/ja active Active
- 2019-12-16 US US16/715,580 patent/US11945859B2/en active Active
- 2019-12-16 CA CA3119241A patent/CA3119241A1/en active Pending
- 2019-12-16 AU AU2019407063A patent/AU2019407063B2/en active Active
- 2019-12-16 WO PCT/IB2019/060859 patent/WO2020128792A1/en active Application Filing
- 2019-12-16 AR ARP190103687A patent/AR117707A1/es unknown
- 2019-12-16 CN CN201980081759.8A patent/CN113194993A/zh active Pending
- 2019-12-16 EP EP19836538.9A patent/EP3897714A1/en active Pending
-
2021
- 2021-05-04 ZA ZA2021/02986A patent/ZA202102986B/en unknown
- 2021-05-25 IL IL283456A patent/IL283456A/en unknown
- 2021-06-15 CO CONC2021/0007830A patent/CO2021007830A2/es unknown
- 2021-06-16 CL CL2021001587A patent/CL2021001587A1/es unknown
- 2021-06-16 EC ECSENADI202143639A patent/ECSP21043639A/es unknown
-
2022
- 2022-04-20 JP JP2022069588A patent/JP2022105056A/ja active Pending
-
2024
- 2024-02-16 US US18/444,288 patent/US20240182554A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR117707A1 (es) | 2021-08-25 |
| US11945859B2 (en) | 2024-04-02 |
| IL283456A (en) | 2021-07-29 |
| MX2021007393A (es) | 2021-09-23 |
| US20240182554A1 (en) | 2024-06-06 |
| US20200190179A1 (en) | 2020-06-18 |
| WO2020128792A1 (en) | 2020-06-25 |
| ECSP21043639A (es) | 2021-07-30 |
| EP3897714A1 (en) | 2021-10-27 |
| KR20210106476A (ko) | 2021-08-30 |
| PE20211602A1 (es) | 2021-08-18 |
| BR112021011290A2 (pt) | 2021-11-03 |
| JP2022513253A (ja) | 2022-02-07 |
| JP7089121B2 (ja) | 2022-06-21 |
| ZA202102986B (en) | 2024-08-28 |
| CN113194993A (zh) | 2021-07-30 |
| AU2019407063A1 (en) | 2021-05-27 |
| CA3119241A1 (en) | 2020-06-25 |
| JOP20210152A1 (ar) | 2023-01-30 |
| CO2021007830A2 (es) | 2021-06-21 |
| SG11202104653XA (en) | 2021-07-29 |
| TW202031289A (zh) | 2020-09-01 |
| AU2019407063B2 (en) | 2024-07-04 |
| JP2022105056A (ja) | 2022-07-12 |
| CR20210318A (es) | 2021-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201700096A (es) | Formulación estable de proteína en solución que contiene una alta concentración de un anticuerpo anti-vegf | |
| CL2021001587A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
| JP6405406B2 (ja) | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 | |
| RU2015132431A (ru) | Составы, содержащие антитела | |
| ECSP099642A (es) | Formulaciones estables de anticuerpo | |
| AR060487A1 (es) | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| JP2017531682A5 (es) | ||
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| AR120512A1 (es) | Formulaciones que contienen anticuerpos | |
| BR112019025591A2 (pt) | Composição farmacêutica compreendendo conjugado de fármaco-anticorpo c-met e uso do mesmo | |
| AR115713A1 (es) | FORMULACIÓN ESTABLE DE ALTA CONCENTRACIÓN PARA ANTICUERPOS ANTI-FXIa | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| AR109252A1 (es) | Formulaciones de anticuerpos |